• Elutia sold its SimpliDerm human acellular dermal matrix business to Cellution Biologics for up to USD 11 million.
• Consideration includes USD 8 million paid at closing, subject to customary inventory and transaction-expense adjustments.
• Deal also provides up to USD 3 million in contingent milestone payments over the next 18 months.
• Proceeds bolster cash resources to support development and commercialization of NXT-41x, with FDA clearance expected in H1 2027.
• Elutia expects funding to cover operations through the first full year of NXT-41x’s commercial launch in 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elutia Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608180800PRIMZONEFULLFEED9811731) on August 18, 2026, and is solely responsible for the information contained therein.